Editas Medicine
Andrew Hirsch is the current Board of Directors at Editas Medicine. Andrew has also served as the Chief Financial Officer at Agios Pharmaceuticals, President & CEO at BIND Therapeutics, and VP, Corporate Strategy and M&A at Biogen Idec. In addition, they were the VP, Finance & Chief Financial Officer at Avila Therapeutics and Epesi Technologies. Hirsch began their career as a Senior Financial Analyst at Stern Stewart & Co.
Andrew Hirsch attended the Wheeler School for their high school education. Andrew then went on to the University of Pennsylvania for their BA, where they studied economics and math. Finally, they attended the Tuck School of Business at Dartmouth for their MBA in general management.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Editas Medicine
5 followers
Editas Medicine is a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Their goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.